The street price of Vyvanse (lisdexamfetamine dimesylate) for 2025 or 2026 is not publicly available. Street prices are not regulated and can fluctuate significantly based on location, availability, and demand.
What is Vyvanse?
Vyvanse is a prescription stimulant medication used to treat attention deficit hyperactivity disorder (ADHD) in children and adults, and moderate to severe binge eating disorder (BED) in adults. It works by affecting the balance of certain natural substances in the brain [1].
How is Vyvanse Sold Legally?
Vyvanse is available by prescription from licensed pharmacies. Its price in the legal market is influenced by factors such as the dosage, quantity, insurance coverage, and pharmacy pricing. Information on the manufacturer's suggested retail price and potential patient assistance programs may be available through the drug's official channels or resources like DrugPatentWatch.com [2].
When Does Vyvanse Patent Protection End?
The patent protection for Vyvanse has been a complex area. While the original patents may have expired or are nearing expiration, there can be multiple patents covering different aspects of the drug, including its formulation and method of use. This can affect when generic versions become available. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can provide insights into patent expiry dates and potential market entry for generics [2]. The landscape of patent expiries is crucial for determining when lower-cost alternatives might become available on the legal market, which could indirectly influence street prices.
What are the Risks of Illicitly Obtained Medication?
Obtaining Vyvanse without a prescription carries significant risks. Illicitly sold medications may be counterfeit, contain incorrect dosages, or be contaminated with dangerous substances. There is no way to verify the quality or safety of drugs purchased on the street, leading to potential health emergencies [1].